Watson Pharmaceuticals News

A subsidiary of Watson Pharmaceuticals is seeking approval for its version of an oral contraceptive from the Food and Drug Administration.

LIVINGSTON, N.J. and PARSIPPANY, N.J., Feb.13, 2012 /PRNewswire/ -- Columbia Laboratories, Inc.

Watson Pharmaceuticals seeks FDA approval to market generic Beyaz after facing a lawsuit from Bayer challenging a patent on the drug.

A unit of Bayer AG, Germany's largest drugmaker, sued Watson Pharmaceuticals Inc., accusing the generic-drug maker of violating a patent for Beyaz birth control pills.

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Drospirenone and Ethinyl Estradiol and Levomefolate Calcium Tablets, 3.0 mg/0.02 mg/0.451 mg and Levomefolate Calcium Tablets, 0.451 mg.

Leading up to Watson Pharmaceuticals ' announcement of its fourth quarter earnings on Tuesday, February 14, 2012, analysts have become more bullish as expectations have improved over the past month from $1.61 per share to the current projection of earnings of $1.75 per share.

S&P 500 component Watson Pharmaceuticals, Inc. will unveil its latest earnings on Tuesday, February 14, 2012.

Join the thousands of real estate professionals that subscribe to the New Jersey AM Alert.

Watson Pharmaceuticals Inc. Chief Executive Officer Paul Bisaro is looking to acquire brand-name drug assets and make a future "'transformational'' purchase as he reshapes the generic-drug maker.

Rambus Inc. : BWS Financial believes Rambus' settlement with NVIDA is a significant positive surprise since it brings an end to a costly legal battle for the company.

NEW YORK &#8212 Watson Pharmaceuticals Inc. said Wednesday it settled a patent lawsuit brought by a unit of Johnson & Johnson over a generic version of the birth control drug Ortho Tri-Cyclen Lo.

If you're interested in finding stocks that may be undervalued, here are some ideas to get started on your search.

Watson Pharmaceuticals Inc. : Leerink says day one of the Lidoderm patent trial produced no surprises, adding it continues to expect Watson Pharmaceuticals to prevail.

Watson Pharmaceuticals, Inc. today announced plans to establish a Global R&D Technology Center in North Brunswick, New Jersey.

PARSIPPANY, N.J., Feb. 3, 2012 /PRNewswire/ -- In response to investment community speculation following release of the transcript of a pre-trial conference call related to its Lidoderm patent challenge, Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that the Company intends to release its fourth quarter 2011 financial results on Tuesday, February 14, 2012 prior to the open of the U.S. financial markets.

Watson Pharmaceuticals Inc. was recently buoyed by the news that the United States Court of Appeals has granted a stay of the preliminary injunction, which was preventing Watson Pharma and partner Amphastar Pharmaceuticals Inc.

The Company has signed a lease for a 32,000-square-foot facility at the New Jersey Economic Development Authority's Technology Centre of The Company plans to immediately retrofit approximately 19,000 square feet of space for product development and analytical laboratories.

Sales of hydrochlorothiazide capsules were about $204 million for the 12 months ending October 2011, according to the pharmaceutical information services and publishing company Wolters Kluwer.

Lannett Company announced it has received approval from the FDA of its Abbreviated New Drug Application for Hydrochlorothiazide Capsules, 12.5 mg.